IFN- treatment cost driver in relapsing-remitting MS

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.458, 2004-01, pp. : 7-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IFN- treatment cost driver in relapsing-remitting MS

Inpharma, Vol. 1, Iss. 1448, 2004-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Novel vaccine show promise for relapsing-remitting MS

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo Hartung Hans-Peter Kurukulasuriya Nuwan C Greenberg Steven J Scaramozza Matthew

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Laquinimod beneficial in relapsing-remitting MS?

Inpharma, Vol. 1, Iss. 1645, 2008-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite